Search the Newsreel

InMode (Nasdaq: INMD) Q2 2026 profit falls as margins narrow

InMode Ltd. (Nasdaq: INMD) reported flat GAAP revenue of $95.6 million for Q2 2026 compared to Q2 2025, but experienced a significant drop in profitability due to narrowing margins. GAAP net income fell to $17.1 million from $26.7 million year-over-year, and diluted EPS decreased …

InMode Reports Second Quarter 2026 Financial Results: Quarterly GAAP Revenues of $95.6 Million, Consistent with the Second Quarter of 2025

InMode Ltd. announced its second-quarter 2026 financial results, reporting GAAP revenues of $95.6 million, consistent with the same period in 2025. Consumables and service revenue increased by 13% to $22.3 million, driven primarily by international sales. The company also provided a financial outlook for …

Modine Manufacturing Company $MOD Position Lessened by Moody National Bank Trust Division

Moody National Bank Trust Division decreased its stake in Modine Manufacturing Company (NYSE:MOD) by 25.4% in the second quarter, selling 7,516 shares and retaining 22,101 shares valued at approximately $5.9 million. Despite this, institutional investors still own 95.23% of the company's stock. Modine Manufacturing …

Moderna, Inc. $MRNA Shares Bought by Quantinno Capital Management LP

Quantinno Capital Management LP increased its stake in Moderna (MRNA) by 74.7% during the first quarter, now owning 168,077 shares worth approximately $8.5 million. Despite beating quarterly revenue and EPS expectations, Moderna remains unprofitable, and analysts maintain a "Reduce" rating with an average price …

Modular Medical to Participate in the Association of Diabetes Care & Education Specialists 2026 Annual Conference

Modular Medical, Inc. will participate in the Association of Diabetes Care & Education Specialists 2026 Annual Conference in Columbus, Ohio, from August 7-10, 2026. The company will showcase its new Pivot™ tubeless insulin patch pump, providing live demonstrations and gathering feedback as it prepares …

Earnings Flash (INMD) InMode Ltd. Posts Q2 Adjusted EPS $0.35 per Share, vs. FactSet Est of $0.33

InMode Ltd. (INMD) announced its Q2 adjusted EPS of $0.35 per share, surpassing the FactSet estimate of $0.33. The company also reported Q2 revenue of $95.6 million, exceeding FactSet's estimate of $93.1 million. This financial update highlights InMode's stronger-than-expected performance for the second quarter.

Modis Navnirman reappoints Dinesh Modi at AGM; reports record FY26 growth

Moderna begins Phase 1 clinical trial of Ebola vaccine against strain behind DRC outbreak

Moderna has initiated a Phase 1 clinical trial for an Ebola vaccine, mRNA-1469, targeting the Bundibugyo strain prevalent in the Democratic Republic of the Congo. The trial, conducted in Canada with approximately 80 participants, will assess the vaccine's safety and tolerability using the same …

Moderna starts Phase 1 trial of mRNA Bundibugyo Ebola vaccine

Moderna has initiated a Phase 1 clinical trial for its mRNA-1469 vaccine, targeting the Bundibugyo ebolavirus strain for which no approved vaccine currently exists. The trial, backed by up to $50 million from CEPI, will enroll approximately 80 healthy adults in Canada to assess …

Health Canada approves clinical trial for Moderna’s mRNA Ebola vaccine

Health Canada has approved Moderna to begin a Phase I clinical trial for an mRNA vaccine targeting the Bundibugyo strain of the Ebola virus, which is causing an outbreak in the Democratic Republic of the Congo. Canada is the second country, after the U.K., …

InMode Deadline Alert

Faruqi & Faruqi, LLP is investigating potential securities claims against InMode Ltd. (NASDAQ: INMD) and reminds investors of the April 15, 2024 deadline to seek the role of lead plaintiff in a federal securities class action. The lawsuit alleges that InMode and its executives …

Moderna begins first human trial of Bundibugyo Ebola vaccine

Moderna has initiated its first human trial for an experimental vaccine targeting the Bundibugyo ebolavirus, a strain responsible for over 1,650 deaths and currently lacking an approved vaccine. The mRNA-based vaccine, mRNA-1469, is being tested in Canada on approximately 80 healthy adults to assess …

Moderna Announces Initiation of Phase 1 Clinical Trial of mRNA-1469, Moderna's Investigational Vaccine Against Bundibugyo Ebolavirus

Moderna has initiated a Phase 1 clinical trial for mRNA-1469, an investigational vaccine targeting Bundibugyo ebolavirus (BDBV), a strain of Ebola with no currently licensed vaccines. The trial, conducted in Canada, is part of an expanded collaboration with CEPI, which has committed up to …

Moderna vaccinates first participants in trial for Ebola strain with no vaccine

Moderna has initiated a Phase 1 clinical trial in Canada for its investigational mRNA vaccine, mRNA-1469, designed to prevent Bundibugyo ebolavirus (BDBV) disease, a strain of Ebola for which no licensed vaccines currently exist. The study will assess the safety, tolerability, and immunogenicity of …

Moderna Begins Human Trial of Experimental Ebola Vaccine in Canada

Moderna has initiated human trials in Canada for an experimental Ebola vaccine, which is the second candidate to enter clinical trials for the strain causing the current outbreak in the Democratic Republic of Congo. The vaccine utilizes Moderna's mRNA platform and is being tested …

Every Few Decades, Aesthetics Gets a New Category. One Preclinical Company Thinks Its Extra Cellular Matrix Platform Could Create the Next One

NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- American News GroupNews Commentary - The multi-billion-dollar medical aesthetics market is built on a handful of category-defining breakthroughs. The neuromodulator category that Botox® created. The hyaluronic-acid filler category. The biostimulator category. Each turned a novel way …

Modern Mills for Food Products Co. Revenue Breakdown – TADAWUL:2284

Sei Investments Co. Acquires 55,939 Shares of Moderna, Inc. $MRNA

Sei Investments Co. increased its stake in Moderna, Inc. by 76.2% in the first quarter, acquiring 55,939 additional shares to bring its total holdings to 129,395 shares valued at approximately $6.6 million. Despite this institutional buying, company insiders have sold a significant number of …

Lazard Asset Management LLC Invests $1.72 Million in Modine Manufacturing Company $MOD

Lazard Asset Management LLC recently acquired 7,945 shares of Modine Manufacturing Company, valued at approximately $1.72 million, increasing institutional ownership to 95.23%. This investment comes despite Modine insiders selling a significant number of shares, totaling $15.93 million, in the last quarter. Analysts currently maintain …

China Modern Dairy Lifts Stake in China Shengmu to 83.5% as Takeover Offer Closes

Why Modine (MOD) Is Down 16.8% After Raising Fiscal 2027 Net Sales Guidance – And What's Next

Modine Manufacturing (MOD) recently reported strong Q1 fiscal 2027 results, with increased sales and net income, and raised its fiscal 2027 net sales guidance by 20% to 35%, driven by demand for its data center and advanced thermal solutions. Despite these positive indicators, the …

Modine Manufacturing Company (MOD) loses active trend as pressure deepens

The auto-parts stock closed July 31 with negative relative strength and elevated turnover, keeping the 52-week weekly setup under strain.

Here's Why We're Not Too Worried About Modern Innovative Digital Technology's (HKG:2322) Cash Burn Situation

Wall Street Cuts MOD Stock Earnings Outlook: Hold or Sell the Stock?

Modine Manufacturing (MOD) shares have dropped significantly, and Wall Street analysts have reduced their earnings outlook for fiscal 2027 and 2028. Despite Modine reporting better-than-expected Q1 2027 earnings, the company faces issues such as falling gross margins, supply bottlenecks, and increasing reliance on a …

Moderna, Inc. (MRNA) Stock Analysis: Exploring a 9.75% Potential Downside in the Biotech Leader

Moderna, Inc. (MRNA) is a biotech leader facing a potential 9.75% downside from its current trading price of $54.82, according to analyst targets. Despite its innovative mRNA technology and strategic partnerships, the company has a negative forward P/E ratio and concerning return on equity, …

Moderna Facing Several Vaccine Headwinds in Near, Medium Term, RBC Says

RBC analysts indicate that Moderna (MRNA) is expected to encounter multiple challenges in its vaccine sector in the near to medium term. The article, reserved for members, suggests these headwinds could impact the company's performance, despite recent news about narrowed Q2 losses and increased …

Modine (MOD) Is Considered a Good Investment by Brokers: Is That True?

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though? Before …

China Modern Dairy Lifts Stake in Shengmu to 83.5% After Offer Close

Modular Medical Picks Five Markets Covering 15% of New Pump Starts

Modular Medical (NASDAQ: MODD) announced the first phase of the commercial launch for its Pivot tubeless patch insulin pump, targeting five key U.S. markets starting October 2026. These markets, including Atlanta, Dallas, and Philadelphia, were chosen for their high concentration of insulin pump prescribers …

Modular Medical Announces Launch of Pivot Insulin Delivery System Across Five Key U.S. Markets Beginning October 2026

Modular Medical, Inc. (NASDAQ:MODD) is launching its Pivot tubeless patch pump in five key U.S. markets starting October 2026: Atlanta, Cincinnati/Lexington, Dallas, Houston, and Philadelphia. This strategic rollout targets areas with high insulin pump adoption and prescribers, aiming to provide a simpler insulin delivery …

Hamilton Wealth LLC Sells 24,338 Shares of Moderna, Inc. $MRNA

Hamilton Wealth LLC decreased its stake in Moderna, Inc. by 23.2% in the first quarter, selling 24,338 shares. Despite mixed institutional investor activity and a generally cautious analyst outlook with a "Reduce" rating, Moderna's recent quarterly results exceeded revenue and EPS expectations. Insiders have …

Amundi Reduces Holdings in Moderna, Inc. $MRNA

Amundi reduced its stake in Moderna, Inc. by 20.9% in the first quarter, selling 238,790 shares and retaining 904,823 shares valued at approximately $46 million. Despite beating reduced earnings expectations, Moderna continues to face substantial losses, declining COVID-19 vaccine demand, and a setback in …

InMode (NASDAQ: INMD) investors back all four AGM proposals

InMode Ltd. shareholders approved all four proposals at their Annual General Meeting held on July 30, 2026. This approval was based on the voting results and complied with Israeli Companies Law and the company’s Articles of Association. A quorum was met with 54.71% of …

Militia Capital Management LLC Buys New Shares in Moderna, Inc. $MRNA

Militia Capital Management LLC acquired 23,001 shares of Moderna, Inc. (NASDAQ:MRNA) worth approximately $1.168 million in the first quarter. This comes as various institutional investors have adjusted their stakes in Moderna, and company insiders have sold shares. The article also provides an overview of …

California State Teachers Retirement System Acquires 11,634 Shares of Modine Manufacturing Company $MOD

The California State Teachers Retirement System increased its holdings in Modine Manufacturing Company (NYSE:MOD) by 24.7% in the first quarter, purchasing an additional 11,634 shares. Other institutional investors also adjusted their positions in Modine, which currently has 95.23% institutional ownership. The company recently reported …

Multi Commodity Exchange of India Shares Decline 2.01% Amid Bearish Sentiment